



# Resveratrol and cardiovascular system—the unfulfilled hopes

Małgorzata Chudzińska<sup>1</sup> · Daniel Rogowicz<sup>2</sup> · Łukasz Wołowicz<sup>2</sup> · Joanna Banach<sup>2</sup> · Sławomir Sielski<sup>2</sup> · Robert Bujak<sup>2</sup> · Anna Sinkiewicz<sup>3</sup> · Grzegorz Grzešek<sup>2</sup>

Received: 3 November 2020 / Accepted: 16 November 2020 / Published online: 21 November 2020  
© Royal Academy of Medicine in Ireland 2020

## Abstract

**Introduction** Resveratrol is a natural polyphenolic compound with a stilbene structure endowed with multiple health-promoting effects. Among phenolic compounds, resveratrol is assigned a leading role in the health-promoting effects of red wine.

**Methods** The aim of the study was to assess the effect of resveratrol on the cardiovascular system in the experimental and clinical studies conducted so far. Moreover, the paper discusses the results of the most recent meta-analyses assessing resveratrol's therapeutic effect on the cardiovascular system in humans.

**Results** In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system. The performed meta-analyses allow to confirm such an impact, however, after the assessment with the use of the SYRCLE's tool, these studies are burdened with a high risk of bias, and the results are not clearly presented.

**Conclusion** Despite numerous articles and clinical studies, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans. Therefore, there is a need for further clinical studies, especially randomized, double-blind, placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential.

**Keywords** Cardiovascular system · Cis-resveratrol · French paradox · Resveratrol · Trans-resveratrol · Wine

## Introduction

Among phenolic compounds, resveratrol is assigned as a leading role in the health-promoting effects of red wine. Is this optimistic opinion confirmed by the documented real impact

of this compound on the human body? How much wine does one need to drink each day for resveratrol to protect one's heart and cardiovascular system?

Resveratrol is a natural polyphenolic compound with a stilbene structure that occurs in two structurally distinct forms,

✉ Daniel Rogowicz  
rogowicz.d@gmail.com

Małgorzata Chudzińska  
malgorzata.chudzinska@cm.umk.pl

Łukasz Wołowicz  
lordtor111@gmail.com

Joanna Banach  
joanna@op.pl

Sławomir Sielski  
sielski@cm.umk.pl

Robert Bujak  
robertbujak@wp.pl

Anna Sinkiewicz  
bizkard@by.onet.pl

Grzegorz Grzešek  
g.grzesek@cm.umk.pl

<sup>1</sup> Department of Nutrition and Dietetics, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 3 Dębowa Street, 85-626 Bydgoszcz, Poland

<sup>2</sup> Department of Cardiology and Clinical Pharmacology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 75 Ujejskiego Street, 85-168 Bydgoszcz, Poland

<sup>3</sup> Department of Phoniatics and Audiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 75 Ujejskiego Street, 85-168 Bydgoszcz, Poland

namely, trans- and cis-resveratrol. Trans-resveratrol is the main active and stable form of resveratrol in grapes and grape juice, but many wines also contain significant amounts of cis-resveratrol [1, 2]. Resveratrol is produced by plants as a defense mechanism against various environmental threats, such as parasitic and fungal infections, ultraviolet radiation, chemical compounds, and mechanical damage [3]. It was first isolated in 1939 from the roots of white hellebore (*Veratrum grandiflorum*) [4], but the richest natural source of resveratrol is considered to be the Japanese knotweed root, which is mainly found in Japan and China. Large amounts of resveratrol were found in red wine, while lower concentrations in white wine, black grape varieties, peanuts, berries, apples, tomato peels, cocoa, and chocolate [5–7]. Concentrations in red wines vary from undetectable to about 14 mg/L, on average about 2 mg/L. In rosé and white wines, the concentrations of this compound are many times lower (even 3–10 times lower in white wines) [8]. The highest concentration of this stilbene is contained in grape skin and seeds, but its content is lower compared to other polyphenolic compounds contained in wine. Red wines with the highest content of resveratrol include Pinot noir, Merlot, Cabernet Sauvignon, Shiraz and the lesser-known strain of St. Laurent and Marzemino.

Resveratrol is absorbed in the jejunum and ileum. Human pharmacokinetic studies with trans-resveratrol have shown very low serum levels of unmetabolized resveratrol after oral administration. Resveratrol is well absorbed after oral administration, but its bioavailability is low and amounts to < 1% due to rapid metabolism in the intestine and liver, which affects the achieved plasma levels [3, 9]. The low bioavailability also results from the glycosylation of resveratrol, which increases the antioxidant capacity of this compound, but at the same time, increases its aqueous solubility, contributing to its increased excretion via urine [10].

On the other hand, high-fat foods delay the absorption of resveratrol. After a few hours, resveratrol metabolites are excreted from the bloodstream via urine and feces [2].

## Health-promoting effect of resveratrol in experimental studies

In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system [11–13]. In experimental studies, resveratrol has shown, among others, that it inhibits the oxidation of cell membrane lipids, protecting low-density lipoproteins (LDL) from oxidation, and increasing the concentration of high-density lipoproteins (HDL). Resveratrol lowers lipid accumulation in human macrophage cultures by affecting cholesterol transport [14–16]. It also exhibits strong antioxidant properties, reducing the production of reactive oxygen species and

scavenging free radicals [17–19]. It has an antithrombotic effect, inhibiting, among others, the synthesis of thromboxane and prostaglandins as well as the activity of platelets and pro-thrombotic mediators [20–22]. In experimental studies conducted in animal models, administration of grape juice or wine decreased the activity of pro-inflammatory cytokines and oxidative stress [23–25].

It has also been found that resveratrol dilates blood vessels in animals by stimulating the synthesis of nitric oxide, which plays a crucial role in protecting the arteries against the development of atherosclerosis [26–28]. In animal studies, the antidiabetic activity of resveratrol was demonstrated, among others, by protective effect on pancreatic cells [29, 30], decreased insulin resistance, and increased insulin content in pancreatic cells by regulating the activity of cellular mitochondria [31, 32].

The results of the conducted experimental studies confirm the occurrence of the above effects. The performed meta-analyses also allow to confirm such an impact, however, their authors emphasize that, after the assessment with the use of the SYRCLE's tool, these studies are burdened with a high risk of bias, and the results are not clearly presented [33].

Chen et al. emphasized that when interpreting animal experimental studies, apart from the result, also the limitations of these studies should be noticed. The occurrence of problems resulting from the low quality of the applied research method, the lack of sample size calculations, and above all, the high risk of bias is particularly important [34]. Summarizing the meta-analysis conducted, Toro et al. noted that most in vivo studies did not contain data that would allow excluding the risk of bias, in line with the SYRCLE's tool [35].

The analysis of the evaluation of the vascular endothelial function and the effect of resveratrol on arterial pressure by Akbari et al. showed that the supplementation of resveratrol significantly increases flow-mediated vasodilation (FMD) with no significant effect of resveratrol on systolic and diastolic pressure [36]. The authors conclude that additional prospective studies are needed to investigate the effects of resveratrol supplementation on endothelial function and blood pressure, and to perform long-term studies, using higher doses of resveratrol with longer durations.

Some authors publish completely contradictory results, the interpretation of which is difficult. Proper design of studies and standardization of their protocols will enable comparison of the studies with each other by means of meta-analyses. This requires the use of modern, repeatable methods as well as the publication of additional source data.

## The anti-dementia and anti-aging effects of resveratrol

Recently, the anti-dementia and anti-aging effects of resveratrol have aroused strong interest among researchers. It has been

shown, among others that long-term limitation of caloric intake in the diet (below 30–50% of the demand) slows down the aging process and thus prolongs the life of many organisms, including rodents and primates [37, 38]. This effect does not occur when genes encoding Sir proteins (silent information regulator, sirtuins) are damaged, but it is enhanced in the case of increased expression of these genes [39]. In vitro and in vivo studies have shown that some red wine polyphenols extend the lifespan and delay the cell aging mechanism by activating sirtuins. Resveratrol is particularly active, as it enzymatically increases the expression of human SIRT1 in vitro by about 13-fold, regulating the lifespan by a similar mechanism as caloric restriction [40, 41]. Resveratrol also inhibits the formation of fat cells and reduces the amount of adipose tissue, which is important in the pathogenesis of cardiovascular and neurodegenerative diseases [42–44]. The conducted studies also confirmed the protective and therapeutic effects of resveratrol in the nervous system, especially in Alzheimer's disease [45, 46]. It has been found in animal models that resveratrol affects the hippocampal cells of the brain, protecting them against the toxic effects of  $\beta$ -amyloid, which is expected to slow down the development of this disease [47]. Moreover, it has also been reported that resveratrol may reduce the predisposition to depressive states, reduce the symptoms of dementia, and improve learning and spatial memory by improving cerebral vascular flow [48–50]. Therefore, the results of the conducted studies give hope that resveratrol could be used to develop new drugs that would inhibit the aging process, preserve youth, health, and vitality for longer [51, 52].

## Clinical studies of resveratrol

It is important to consider how the diverse potential of resveratrol translates into its health-promoting effects in clinical studies, and what is the benefit for the heart and vessels of consuming one or two glasses of red wine and resveratrol it contains? In order to use strong arguments in response, data from studies with the highest impact, i.e., resulting from meta-analyses of randomized clinical studies, were taken into account. These publications are few and between, and not always consistent, but they shed light on the clinical health-promoting effects of resveratrol.

Resveratrol has been shown to be effective in humans with hypertension, but mostly when using high doses above 300 mg/day [50] or 150 mg/day [53, 54]. In humans with obesity or overweight, it allowed for weight loss [55, 56]. In humans suffering from diabetes, a reduction in fasting glucose levels and glycosylated hemoglobin (HbA1C), and an increase in insulin sensitivity were observed at doses over 100 mg/day [57]. The results of clinical studies concerning the resveratrol's positive effect on the lipid metabolism seem to be rather weak, as no significant reduction in LDL cholesterol

was observed [58]. Moreover, in one of the randomized studies using a dose of 150 mg/day or 1000 mg/day for 16 weeks in 74 humans with metabolic syndrome, a significant increase in both LDL and total cholesterol levels was observed [59]. The results of meta-analyses of randomized clinical studies on the resveratrol's anti-inflammatory activity are also quite inconsistent, as both a decrease in CRP and IL-6 levels was observed [60, 61] or no changes in CRP levels were noted [62]. The results of clinical studies assessing the beneficial effect of resveratrol, both in humans with chronic coronary disease [63, 64] and left ventricular dysfunction after myocardial infarction [65] were also not convincing and required further well-designed studies.

## Wine, resveratrol, and the French paradox

A scientific promoter of the French paradox, Prof. Serge Renaud, formulated a theory of lower incidence and mortality due to ischemic heart disease among the inhabitants of the Bordeaux region, despite high levels of dietary saturated fat and cigarette smoking, which he justified with consumption of red wine with meals (customary in this part of Europe) and the polyphenols contained in it [66]. Over the years, this beneficial role has been increasingly attributed to resveratrol.

It should be remembered that the current recommendations regarding the daily health-promoting dose of this compound are based mainly on arithmetical animal-to-human dosage conversion. Based on these calculations, it was concluded that a dose of 1 g/day resveratrol could be both an effective and a safe dose. In the randomized clinical studies mentioned above, daily doses of resveratrol ranged from 100 mg to 1 g.

While critically assessing the role of resveratrol in the French paradox, attention should be paid not only to the low bioavailability of this compound, resulting mainly from the rapid elimination of resveratrol from the body, but also to the fact that the transfer of results from in vitro studies and animal models to humans have not brought the expected results so far. The concentrations used in these studies are much higher than can be obtained in the human body with the habitual consumption of red wine. It is possible to achieve higher concentrations of resveratrol in human plasma, but only by using additional resveratrol-enriched supplements, even at the promoted dose of 1 g/day. Various reports of mediocre or no scientific value try to convince the consumer that the resveratrol contained in the supplements allows to achieve an health-promoting effect and protect the heart from a myocardial infarction.

The concentration of resveratrol in wine varies depending on the type of strain, vineyard, microclimate, and year. Different wine-making processes, including temperature, obtained pH, and sulfur dioxide content in wine, also influence the concentration of resveratrol. However, all these factors

make it difficult to precisely determine the content of this substance contained in natural products [67, 68].

This raises the question: what dose of resveratrol should be considered clinically effective and safe at the same time? In clinical studies with volunteers, the high doses of 2–5 g resveratrol/day were safe, but often caused gastrointestinal discomfort. Much lower dosages of 100–300 mg/day, also allowed to achieve a therapeutic effect in randomized clinical studies, which this gave rise to another scientific dilemma: what doses of resveratrol should be used in specific diseases without concerns about the safety of the drug [69, 70]? Considering the resveratrol contained in red wine, the question is, how much would one need to drink per day to reach a dose of at least 100 mg resveratrol/day?

The average concentration of resveratrol in red wines ranges from 0.36 to 2.0 mg/L [71]; in white wines, it is much lower from 0 to 1.1 mg/L [72]; and in rosé wines, it is approximately 0.3 mg/L [73]. According to 2014 data from the Global Agricultural Information Network, an average French drinks about 44 L of wine a year, of which 75% are red wines and 25% white wines [74]. Assuming that red wine contains about 2 mg/L resveratrol, a consumption of 44 L of wine is equals 70 mg resveratrol/year or 0.2 mg/day, which is 500 times less than the dose of 100 mg/day. This means that one would need to drink 50 L of wine or eat 250 kg of apples daily to achieve the beneficial health effects associated with resveratrol. Even including resveratrol contained in other natural products, this calculation clearly proves that consuming resveratrol contained in natural products is not enough to explain the mechanism of the French paradox. Especially since one cannot be sure whether higher doses would be safe for the heart.

Studies conducted on rats show that even doses of above 25 mg/day increased the area of myocardial infarction and cardiomyocyte apoptosis [75]. One more important question should be asked—is resveratrol supplementation always safe for health? Bearing in mind that the exact molecular mechanism responsible for the pleiotropic beneficial effects of this compound remains unclear and controversial, the safety of resveratrol-enriched supplements is also questioned. Resveratrol can inhibit platelet aggregation in humans *in vitro*, therefore, theoretically, high resveratrol intake may increase the risk of bleeding in people taking anticoagulants, antiplatelet drugs, and non-steroidal anti-inflammatory drugs [22].

## Conclusion

More than 80 years have passed since the first isolation of resveratrol in 1939 from the roots of the white hellebore. More than 20,000 articles related to resveratrol have been published and more than 130 clinical studies have been

conducted, however, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans [76]. Therefore, there is a need for further clinical studies, especially randomized, double-blind, and placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential, both in natural products, including wine and in resveratrol-enriched supplements. Therefore, while waiting for convincing scientific data, there is nothing left but to consume red wine with the optimistic conviction that resveratrol contained in this drink has a positive effect on health.

**Authors' contributions** MC—conception and design of the article, interpreting the relevant literature, drafting of manuscript;

DR—conception and design of the article, interpreting the relevant literature, drafting of manuscript;

LW—interpreting the relevant literature, drafting of manuscript;

JB—interpreting the relevant literature, drafting of manuscript;

SS—conception and design of the article, interpreting the relevant literature;

RB—literature review, drafting of manuscript;

AS—literature review, critical revision;

GG—critical revision, proofreading of the version for publication.

All authors read and approved the final manuscript.

## Compliance with ethical standards

**Competing interests** The authors declare that they have no competing interests.

**Ethics approval** Not applicable

**Consent to participate** Not applicable

**Consent for publication** Not applicable

## References

1. Trela BC, Waterhouse AL (1996) Resveratrol Isomeric molar absorptivities and stability. *J Agric Food Chem* 44:1253–1257. <https://doi.org/10.1021/jf9504576>
2. Pantusa M, Bartucci R, Rizzuti B (2014) Stability of trans-resveratrol associated with transport proteins. *J Agric Food Chem* 62:4384–4391. <https://doi.org/10.1021/jf405584a>
3. Gambini J, Inglés M, Olaso G et al (2015) Properties of resveratrol: *in vitro* and *in vivo* studies about metabolism, bioavailability, and biological effects in animal models and humans. *Oxid Med Cell Longev*. <https://doi.org/10.1155/2015/837042>
4. Takaoka M (1939) Resveratrol, a new phenolic compound, from *Veratrum grandiflorum*. *Nippon Kagaku Kaishi (J Chem Soc Jpn)* 60:1090–1100. <https://doi.org/10.1246/nikkashi1921.60.1090>
5. Burns J, Yokota T, Ashihara H et al (2002) Plant foods and herbal sources of resveratrol. *J Agric Food Chem* 50:3337–3340. <https://doi.org/10.1021/jf0112973>
6. Sales JM, Resurreccion AV (2014) Resveratrol in peanuts. *Crit Rev Food Sci Nutr* 54:734–770. <https://doi.org/10.1080/10408398.2011.606928>

7. Counet C, Callemien D, Collin S (2006) Chocolate and cocoa: new sources of trans-resveratrol and trans-piceid. *Food Chem* 98:649–657. <https://doi.org/10.1016/j.foodchem.2005.06.030>
8. Presta MA, Bruyneel B, Zanella R et al (2009) Determination of Flavonoids and Resveratrol in Wine by Turbulent-Flow Chromatography-LC-MS. *Chromatographia* 69:167–173. <https://doi.org/10.1365/s10337-009-1132-x>
9. Walle T, Hsieh F, DeLegge MH et al (2004) High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab Dispos* 32:1377–1382. <https://doi.org/10.1124/dmd.104.000885>
10. Smoliga JM, Blanchard O (2014) Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? *Molecules* 19:17154–17172. <https://doi.org/10.3390/molecules191117154>
11. Bonnefont-Rousselot D (2016) Resveratrol and cardiovascular diseases. *Nutrients* 8:250. <https://doi.org/10.3390/nu8050250>
12. Breuss JM, Atanasov AG, Uhrin P (2019) Resveratrol and its effects on the vascular system. *Int J Mol Sci* 20:1523. <https://doi.org/10.3390/ijms20071523>
13. Cheng CK, Luo JY, Lau CW (2020) Pharmacological basis and new insights of resveratrol action in the cardiovascular system. *Br J Pharmacol* 177:1258–1277. <https://doi.org/10.1111/bph.14801>
14. Yashiro T, Nanmoku M, Shimizu M et al (2012) Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. *Atherosclerosis* 220:369–374. <https://doi.org/10.1016/j.atherosclerosis.2011.11.006>
15. Berrougui H, Grenier G, Loued S et al (2009) A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. *Atherosclerosis* 207:420–427. <https://doi.org/10.1016/j.atherosclerosis.2009.05.017>
16. Sahebkar A (2013) Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 71:822–835. <https://doi.org/10.1111/nure.12081>
17. Vislocky LM, Fernandez ML (2010) Biomedical effects of grape products. *Nutr Rev* 68:656–670. <https://doi.org/10.1111/j.1753-4887.2010.00335.x>
18. Xia N, Daiber A, Forstermann U, Li H (2017) Antioxidant effects of resveratrol in the cardiovascular system. *Br J Pharmacol* 174:1633–1646. <https://doi.org/10.1111/bph.13492>
19. Frombaum M, Le Clanche S, Bonnefont-Rousselot D et al. (2012) Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and, NO bioavailability: potential benefits to cardiovascular diseases. *Biochimie* 94:269–276. <https://doi.org/10.1016/j.biochi.2011.11.001>
20. Wang Z, Huang Y, Zou J (2002) Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. *Int J Mol Med* 9:77–79. <https://doi.org/10.3892/ijmm.9.1.77>
21. Pace-Asciak CR, Hahn S, Diamandis EP (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. *Clin Chim Acta* 235:207–219. [https://doi.org/10.1016/0009-8981\(95\)06045-1](https://doi.org/10.1016/0009-8981(95)06045-1)
22. Bertelli AA, Giovannini L, Giannessi DA et al. (1995) Antiplatelet activity of synthetic and natural resveratrol in red wine. NIH National library of medicine. <https://pubmed.ncbi.nlm.nih.gov/7499059/>. Accessed 03 November 2020
23. Ghanim H, Sia CL, Korzeniewski K et al (2011) A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. *J Clin Endocrinol Metab* 96:1409–1414. <https://doi.org/10.1210/jc.2010-1812>
24. Malaguamera L (2019) Influence of resveratrol on the immune response. *Nutrients* 11:946. <https://doi.org/10.3390/nu11050946>
25. Das S, Das DK (2007) Anti-inflammatory responses of resveratrol. *Inflamm. Allergy Drug Targets* 6:168–173. <https://doi.org/10.2174/187152807781696464>
26. Wallerath T, Deckert G, Ternes T et al (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. *Circulation* 106:1652–1658. <https://doi.org/10.1161/01.CIR.0000029925.18593.5C>
27. Leikert JF, Räthel TR, Wohlfart P et al (2002) Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. *Circulation* 106:1614–1617. <https://doi.org/10.1161/01.CIR.0000034445.31543.43>
28. Takahashi S, Nakashima Y (2012) Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. *Br J Nutr* 107:774–780. <https://doi.org/10.1017/S0007114511003588>
29. Cheng AS, Cheng YH, Lee CY et al (2015) Resveratrol protects against methylglyoxal-induced hyperglycemia and pancreatic damage in vivo. *Nutrients* 7:2850–2865. <https://doi.org/10.3390/nu7042850>
30. Szkudelski T, Szkudelska K (2015) Resveratrol and diabetes: from animal to human studies. *Biochim Biophys Acta* 1852:1145–1154. <https://doi.org/10.1016/j.bbadis.2014.10.013>
31. Hausenblas HA, Schoulda JA, Smoliga JM (2015) Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus: systematic review and meta-analysis. *Mol Nutr Food Res* 59:147–159. <https://doi.org/10.1002/mnfr.201400173>
32. Kong W, Chen LL, Zheng J et al (2015) Resveratrol supplementation restores high-fat diet-induced insulin secretion dysfunction by increasing mitochondrial function in islet. *Exp Biol Med* 240:220–229. <https://doi.org/10.1177/1535370214548998>
33. Andrade EF, Orlando DR, Araújo AMS et al (2019) Can resveratrol treatment control the progression of induced periodontal disease? A systematic review and meta-analysis of preclinical studies. *Nutrients* 11:953. <https://doi.org/10.3390/nu11050953>
34. Chen JY, Zhu Q, Zhang S et al (2019) Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies. *Pharmacol Res* 150:104476. <https://doi.org/10.1016/j.phrs.2019.104476>
35. Toro MD, Nowomiejska K, Avitabile T et al (2019) Effect of Resveratrol on In Vitro and In Vivo Models of Diabetic Retinopathy: A Systematic Review. *Int J Mol Sci* 20:3503. <https://doi.org/10.3390/ijms20143503>
36. Akbari M, Tamtaji OR, Lankarani KB (2019) The effects of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. *High Blood Press Cardiovasc Prev* 26:305–319. <https://doi.org/10.1007/s40292-019-00324-6>
37. Heilbronn LK, Ravussin E (2003) Calorie restriction and aging: review of the literature and implication for studies in humans. *Am J Clin Nutr* 78:361–369. <https://doi.org/10.1093/ajcn/78.3.361>
38. Das DK, Mukherjee S, Ray D (2010) Resveratrol and red wine, healthy heart and longevity. *Heart Failure Reviews* 15:467–477. <https://doi.org/10.1007/s10741-010-9163-9>
39. Lee SH, Lee JH, Lee HY et al (2019) Sirtuin signaling in cellular senescence and aging. *BMB Rep* 52:24–34. <https://doi.org/10.5483/BMBRep.2019.52.1.290>
40. Cao D, Wang M, Qiu X et al (2015) Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. *Genes Dev* 29:1316–1325. <https://doi.org/10.1101/gad.265462.115>
41. Porcu M, Chiarugi A (2005) The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. *Trends Pharmacol Sci* 26:94–103. <https://doi.org/10.1016/j.tips.2004.12.009>

42. Fernandez-Quintela A, Milton-Laskibar I, Gonzalez M et al (2017) Antiobesity effects of resveratrol: which tissues are involved? *Ann N Y Acad Sci* 403:118–131. <https://doi.org/10.3389/fendo.2019.00413>
43. Tabrizi R, Tamtaji OR, Lankarani KB (2018) The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 13:1–16. <https://doi.org/10.1080/10408398.2018.1529654>
44. Zhao Y, Chen B, Shen J (2017) The beneficial effects of quercetin, curcumin, and resveratrol in obesity. *Oxid Med Cell Longev* 2017: 1459497. <https://doi.org/10.1155/2017/1459497>
45. Li YR, Li S, Lin CC (2018) Effect of resveratrol and pterostilbene on aging and longevity. *Biofactors* 44:69–82. <https://doi.org/10.1002/biof.1400>
46. Bastianetto S, Ménard C, Quirion R (2015) Neuroprotective action of resveratrol. *Biochimica et Biophysica Acta* 6:1195–1201. <https://doi.org/10.1016/j.bbadis.2014.09.011>
47. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. *J Biol Chem* 280:37377–37382. <https://doi.org/10.1074/jbc.M508246200>
48. Zhu X, Li W, Li Y (2019) The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition. *Neuropharmacology* 15:153:20–31. <https://doi.org/10.1016/j.neuropharm.2019.04.022>
49. Lange KW, Li S (2018) Resveratrol, pterostilbene, and dementia. *Biofactors* 44:83–90. <https://doi.org/10.1002/biof.1396>
50. Cicero AFG, Ruscica M, Banach M (2019) Resveratrol and cognitive decline: a clinician perspective. *Arch Med Sci* 15:936–943. <https://doi.org/10.5114/aoms.2019.85463>
51. Bhullar KS, Hubbard BP (2015) Lifespan and healthspan extension by resveratrol. *Biochim. Biophys Acta* 1852:1209–1218. <https://doi.org/10.1016/j.bbadis.2015.01.012>
52. Hector KL, Lagisz M, Nakagawa S (2012) The effect of resveratrol on longevity across species: a meta-analysis. *Biology Letters* 8: 790–793. <https://doi.org/10.1098/rsbl.2012.0316>
53. Fogacci F, Tocci G, Presta V et al (2019) Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. *Crit Rev Food Sci Nutr* 59:1605–1618. <https://doi.org/10.1080/10408398.2017.1422480>
54. Liu Y, Ma W, Zhang P et al (2015) Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. *Clin Nutr* 34:27–34. <https://doi.org/10.1016/j.clnu.2014.03.009>
55. Mousavi SM, Milajerdi A, Sheikhi A et al (2019) Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. *Obes Rev* 20:487–498. <https://doi.org/10.1111/obr.12775>
56. Tabrizi R, Tamtaji OR, Lankarani K et al (2020) The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr* 60:375–390. <https://doi.org/10.1080/10408398.2018.1529654>
57. Zhu X, Wu C, Qiu S (2017) Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. *Nutr Metab* 14:60. <https://doi.org/10.1186/s12986-017-0217-z>
58. Haghghatdoost F, Hariri M (2018) Effect of resveratrol on lipid profile: an updated systematic review and meta-analysis on randomized clinical trials. *Pharmacol Res* 129:141–150. <https://doi.org/10.1016/j.phrs.2017.12.033>
59. Kjaer TN, Ornstru MJ, Poulsen MM et al (2017) No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. *J Clin Endocrinol Metab* 102: 1642–1651. <https://doi.org/10.1210/jc.2016-2160>
60. Haghghatdoost F, Hariri M (2019) Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials. *Eur J Clin Nutr* 73:345–355. <https://doi.org/10.1038/s41430-018-0253-4>
61. Koushki M, Dashatan NA, Meshkani R (2018) Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. *Clin Ther* 40:1180–1192. <https://doi.org/10.1016/j.clinthera.2018.05.015>
62. Sahebkar A, Serban C, Ursoniu S et al (2015) Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—results from a systematic review and meta-analysis of randomized controlled trials. *Int J Cardiol* 189:47–55. <https://doi.org/10.1016/j.ijcard.2015.04.008>
63. Magyar K, Halmosi R, Palfi A et al (2012) Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. *Clin Hemorheol Microcirc* 50:179–187. <https://doi.org/10.3233/CH-2011-1424>
64. Raj P, Zieroth S, Neticadan T (2015) An overview of the efficacy of resveratrol in the management of ischemic heart disease. *Ann N Y Acad Sci* 1348:55–67. <https://doi.org/10.1111/nyas.12828>
65. Raj P, Louis XL, Thandapilly SJ et al (2014) Potential of resveratrol in the treatment of heart failure. *Life Sci* 95:63–71. <https://doi.org/10.1016/j.lfs.2013.12.011>
66. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. *Lancet* 339:1523–1526. [https://doi.org/10.1016/0140-6736\(92\)91277-f](https://doi.org/10.1016/0140-6736(92)91277-f)
67. Stervbo U, Vang O, Bonnesen C (2007) A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. *Food Chem* 101:449–457. <https://doi.org/10.1016/j.foodchem.2006.01.047>
68. Pastor RF, Restani P, Di Lorenzo C (2019) Resveratrol, human health and winemaking perspectives. *Crit Rev Food Sci Nutr* 59: 1237–1255. <https://doi.org/10.1016/j.foodchem.2006.01.047>
69. Chow HH, Garland LL, Hsu CH et al (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. *Cancer Prev Res (Phila)* 3:1168–1175. <https://doi.org/10.1158/1940-6207.CAPR-09-0155>
70. Brasnyó P, Molnár GA, Mohás M et al (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. *Br J Nutr* 106:383–389. <https://doi.org/10.1017/S0007114511000316>
71. Jeandet P, Bessis R, Maume BF et al (1993) Analysis of resveratrol in burgundy wines. *J Wine Res* 4:79. <https://doi.org/10.1080/09571269308717954>
72. Romero-Pérez AI, Lamuela-Raventós RM, Buxaderas S (1996) Torre-Boronat MC. Resveratrol and piceid as varietal markers of white wines. *J Agric Food Chem* 44:1975–1978. <https://doi.org/10.1080/09571269308717954>
73. Cvejic JM, Djekic SV, Petrovic AV (2010) Determination of *trans*- and *cis*-resveratrol in Serbian commercial wines. *J Chromatogr Sci* 48:229–234. <https://doi.org/10.1080/09571269308717954>
74. Global Agricultural Information Network (2015) Wine Annual Report and Statistics 2015 (GAIN Report Number IT1512) [https://apps.fas.usda.gov/newgainapi/api/report/downloadreportbyfilename?filename=Wine%20Annual\\_Rome\\_EU-28\\_3-16-2015.pdf](https://apps.fas.usda.gov/newgainapi/api/report/downloadreportbyfilename?filename=Wine%20Annual_Rome_EU-28_3-16-2015.pdf)
75. Dudley J, Das S, Mukherjee S et al (2009) Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. *J Nutr Biochem* 20:443–452. <https://doi.org/10.1016/j.jnutbio.2008.05.003>
76. Pezzuto JM (2019) Resveratrol: twenty years of growth, development and controversy. *Biomol Ther (Seoul)* 27:1–14. <https://doi.org/10.4062/biomolther.2018.176>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.